Voice-activated Intelligent Personal Assistant (VIPA) Intervention for People With Parkinson's Disease
- Conditions
- Parkinson's Disease and Parkinsonism
- Interventions
- Device: Voice-activated Intelligent Personal Assistant (VIPA)
- Registration Number
- NCT06036771
- Lead Sponsor
- The Hong Kong Polytechnic University
- Brief Summary
This pilot randomized control trial (RCT) aims to develop a Voice-activated Intelligent Personal Assistance (VIPA) user protocol and study its feasibility and preliminary efficacy among 60 People with Parkinson's disease (PWP). The research questions are:
Phase 1:
1. What components should be included in the VIPA user protocol community-dwelling PWP?
2. Is it feasible to implement the VIPA intervention in the PD population?
3 focus group interviews and 3 cognitive interviews will be held to formulate the VIPA user protocol. 5 healthcare and information technology experts will be invited to rate the relevancy of the formulated protocol and the item content validity index will be calculated by the researcher.
Phase 2:
1. What is the preliminary efficacy of VIPA intervention on SOC and psychosocial well-being?
2. Can such effect sustain for 4 weeks?
3. What is the users' experience on the VIPA intervention?
60 participants will be randomized into the intervention group (IG) and control group (CG). During the 8-week intervention period, IG participants will receive the following materials:
1. User protocol
2. Designate VIPA
3. 30-minute VIPA training on day 1
4. Weekly technical support phone calls. CG participants will receive usual care, no intervention will be provided to CG participants, and they will continue their daily life during the intervention period.
The researcher will compare both groups to study the feasibility and preliminary efficacy of the VIPA on the participants' psychosocial well-being and sense of coherence.
- Detailed Description
Background:
Parkinson's disease (PD) is one of the two most common neurodegenerative diseases affecting millions worldwide. PD research generally focuses on motor functioning and calls for more psychosocial interventions for people with Parkinson's disease (PWP).
The proposed VIPA intervention is an artificial intelligent personal assistant commonly used within Western society but not Asian countries, facilitating users' daily living by performing audio calls, messaging, and information searching. Recent literature showed VIPA Implementation is promising for rehabilitation in older adults but warrants more interventional studies to examine its efficacy and if it applies to other illnesses. Therefore, this study will formulate a positive health-orientated VIPA intervention protocol and investigate its efficacy in promoting PWP's sense of coherence and psychosocial well-being.
Objectives of the study:
This is a 2-phase study, and the objectives are:
Phase 1:
1. To develop and validate the VIPA user protocol.
2. To examine the feasibility of the VIPA intervention.
Phase 2:
1. To investigate the preliminary efficacy of the VIPA intervention on PWP's SOC
2. To explore the users' experience of VIPA intervention among PWP.
Method:
Phase 1: 3 semi-structured focus group interviews will be held to generate items in user protocol. Another 3 cognitive interviews will be held with PWP to test the face validity and feasibility of the user protocol. 5 healthcare and information technology experts will then be invited to assess the content validity of the protocol. Any item with an item content validity index (i-CVI) score lower than 0.78 will be discarded or revised.
Phase 2: 60 participants will be randomized into the intervention group (IG) and control group (CG). During the 8-week intervention period, IG participants will receive the user protocol, a designated VIPA, a 30-minute VIPA training on day 1, and weekly technical support phone calls. CG participants will receive usual care (no intervention will be provided to CG participants), and they will continue their daily life during the intervention period. The 13-item Sense of Coherence Scale (SOC-13) will be set as the primary outcome, and secondary outcomes are: 1. University of California, Los Angeles (UCLA) three-item loneliness scale; 2. Parkinson's Disease Questionnaire (PDQ-8); 3. EuroQol-5 dimension-5 level; 4. Mental Health Continuum Short Form; 5. System Usability Scale; 6. Brief Resilient Coping Scale; 7. Montreal Cognitive Assessment; and 8. Self-report VIPA usage.
12 participants will then be selected through extreme case sampling to partake in explanatory, in-depth interviews based on their SOC-13 score differences between baseline and post-intervention tests to explore VIPA user experience.
Data analysis:
For qualitative data, content analysis will be used in phase 1, while in phase 2, in-depth interview data will be analyzed through deductive thematic analysis according to the salutogenic model. Quantitative data, such as demographic data, will be presented with descriptive statistics. Chi-square test and independent t-test will be performed for baseline comparison. Generalized Estimating Equations will be used to analyze group differences in all primary and secondary outcomes.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Cantonese-speaking Hong Kong permanent resident
- Diagnosed with Parkinson's disease
- Level 1-4 in the H&Y scale (Hoehn & Yahr, 1967)
- Not currently using or owning VIPA
- Has stable Wi-Fi connection at home.
- PWP or their caregivers that fails to provide valid consent
- Individuals with hearing loss in both ears
- Severe voice impairment
- Dementia patients (MoCA score <21)
- PWP will leave Hong Kong during the intervention period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Voice-activated Intelligent Personal Assistant (VIPA) intervention Voice-activated Intelligent Personal Assistant (VIPA) IG participants will receive 1. The developed VIPA user protocol 2. 30-minute training session on day 1 3. Weekly technical tele-support Dosage of the intervention: PWP are encouraged to perform 10 voice commands/ day during the 8-week intervention period, self-reported usage will be documented by participants in a progress note.
- Primary Outcome Measures
Name Time Method 13-item Sense of Coherence Scale [Time Frame: Baseline; 8 weeks; 12 weeks] The 13-item Sense of Coherence Scale is a 13 item, 7-point Likert scale that measures PWP's sense of coherence. Its score ranges from 13-91, with a higher score representing a higher sense of coherence.
- Secondary Outcome Measures
Name Time Method Self-report VIPA usage [Time Frame: 8 weeks] PWP will report self-report VIPA usage across the intervention period. A logbook will be provided to PWP to log down their daily usage.
Mental Health Continuum Short Form [Time Frame: Baseline; 8 weeks; 12 weeks] The Mental Health Continuum Short Form is a 14 item, 6-point Likert scale measuring PWP's psychosocial well-being. Its score ranges from 0-70, with a higher score indicating higher psychosocial well-being.
Parkinson's Disease Questionnaire (PDQ-8) [Time Frame: Baseline; 8 weeks; 12 weeks] Parkinson's Disease Questionnaire (PDQ-8) is an 8 item, 5-point Likert scale commonly adopted to measure PWP's quality of life. The higher summative score indicates a lower quality of life experienced.
UCLA three-item loneliness scale [Time Frame: Baseline; 8 weeks; 12 weeks] The UCLA three-item loneliness scale is a 3 item, 3-point Likert scale that measures PWP's perceived loneliness. Its score ranges from 3-9, with a higher score indicating a more lonely sensation.
EuroQol- 5 dimension- 5 level [Time Frame: Baseline] EuroQol- 5 dimension- 5 level utilized a visual analogue scale from 1-100 and 5 descriptive statements to explore an individual's quality of life. This scale is adopted to validate the newly translated PDQ-8
Brief Resilient Coping Scale [Time Frame: Baseline; 8 weeks; 12 weeks] The Brief Resilient Coping Scale is a 4 item, 5-point Likert scale measuring an individual's coping. Its score ranges from 4-20, with a higher score indicating better coping.
Montreal Cognitive Assessment (MoCA) [Time Frame: Screening; 8 weeks; 12 weeks] The Montreal Cognitive Assessment (MoCA) is a professional administrated assessment to evaluate an individual's cognitive functioning. This scale will be first administered to screen out PWP with dementia. Its score ranges from 0-30, with a higher score representing higher cognitive functioning.
System Usability Scale [Time Frame: 8 weeks] System Usability Scale is a 10 item,5-point Likert scale that assess the usability of the implemented intervention. Its score ranges from 0-100, with a higher score indicates a higher usability
Trial Locations
- Locations (1)
The Hong Kong Polytechnic University
ðŸ‡ðŸ‡°Kowloon, Hong Kong